1. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers
- Author
-
Tricia H. Burdo, Janet Lo, Kenneth C. Williams, Maria J. Buzon, Florencia Pereyra, Kathleen V. Fitch, Virginia A. Triant, Steven K. Grinspoon, Janice Hwang, Jennifer H. Campbell, Jeffrey Wei, and Suhny Abbara
- Subjects
Male ,Immunology ,Human immunodeficiency virus (HIV) ,HIV Infections ,Viremia ,Coronary Artery Disease ,Lymphocyte Activation ,medicine.disease_cause ,Article ,Prevalence ,medicine ,Humans ,Immunology and Allergy ,Coronary atherosclerosis ,medicine.diagnostic_test ,business.industry ,Monocyte ,Angiography ,Calcinosis ,virus diseases ,Middle Aged ,Viral Load ,medicine.disease ,CD4 Lymphocyte Count ,Infectious Diseases ,medicine.anatomical_structure ,Disease Progression ,HIV-1 ,Female ,business ,Viral load ,Elite controllers ,Immune activation - Abstract
HIV-1 elite controllers spontaneously maintain suppressed levels of viremia, but exhibit significant immune activation. We investigated coronary atherosclerosis by coronary computed tomography angiography (CTA) in elite controllers, nonelite controller, chronically HIV-1 infected, antiretroviral therapy (ART)-treated patients with undetectable viral load ('chronic HIV'), and HIV-negative controls. Prevalence of atherosclerosis (78 vs. 42%, P < 0.05) and markers of immune activation were increased in elite controllers compared with HIV-negative controls. sCD163, a monocyte activation marker, was increased in elite controllers compared with chronic HIV-1 (P < 0.05) and compared with HIV-negative controls (P < 0.05). These data suggest a significant degree of coronary atherosclerosis and monocyte activation among elite controllers.
- Published
- 2012
- Full Text
- View/download PDF